A prospective, observational trial to assess the safety and efficacy of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter Ducreux Michel
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors D. Michel1, F. Alfredo2, C.J.A. Punt3, K. Svetlana4, O.J. Manuel5, C. Andres6
  • 1Gustave Roussy Cancer Campus Grand Paris, Villejuif, France, /
  • 2Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, /
  • 3Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, /
  • 4Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, USA, /
  • 5Institute Alexander Fleming, Buenos Aires, Argentina, /
  • 6University Hospital of Valencia, Valencia, Spain, /

Abstract

Two randomized, double-blind, phase 3 trials have shown that the oral multikinase inhibitor regorafenib significantly improves overall survival vs placebo in patients with mCRC that has progressed on available treatments (Grothey A, Van Cutsem E, et al. Lancet 2013;381:303–312; Li J, et al. Lancet Oncol 2015;16:619–629). The aim of CORRELATE is to characterize the safety and efficacy of regorafenib for the treatment of mCRC in an unselected real-world patient population treated in routine clinical practice.